NCT04209712 is a EARLY_PHASE1 clinical trial of haploid allogeneic NK cell therapy in Acute Myeloid Leukemia, sponsored by Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China.

Who is sponsoring NCT04209712?

NCT04209712 is sponsored by Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China.

What drugs are being tested in NCT04209712?

Interventions in NCT04209712: haploid allogeneic NK cell therapy.

What condition does NCT04209712 study?

NCT04209712 studies Acute Myeloid Leukemia.

Is NCT04209712 still recruiting?

NCT04209712 is currently status unknown. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT04209712

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Status unknown EARLY_PHASE1 Last updated 29 July 2020

What this trial tests

EARLY_PHASE1 trial testing haploid allogeneic NK cell therapy in Acute Myeloid Leukemia in 6 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 January 2020
Primary completion	31 December 2020
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

haploid allogeneic NK cell therapy — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →

Sponsor

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China — full company profile →

Who can join

Adults 1 to 80, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, et al · · 2022 · cited 125× · PMID 36348457 · DOI 10.1186/s13045-022-01382-5
Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J, Niu T. · · 2020 · cited 83× · PMID 33287858 · DOI 10.1186/s13045-020-00996-x
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Aitken MJL, Ravandi F, Patel KP, Short NJ. · · 2021 · cited 40× · PMID 34479626 · DOI 10.1186/s13045-021-01148-5
MRD Tailored Therapy in AML: What We Have Learned So Far.
Ngai LL, Kelder A, Janssen JJWM, Ossenkoppele GJ, et al · · 2020 · cited 37× · PMID 33575214 · DOI 10.3389/fonc.2020.603636
Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
Kent A, Crump LS, Davila E. · · 2023 · cited 21× · PMID 37654497 · DOI 10.3389/fimmu.2023.1202950
Natural killer cells and acute myeloid leukemia: promises and challenges.
Rahmani S, Yazdanpanah N, Rezaei N. · · 2022 · cited 20× · PMID 35639116 · DOI 10.1007/s00262-022-03217-1
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
Meddi E, Savi A, Moretti F, Mallegni F, et al · · 2023 · cited 12× · PMID 36834477 · DOI 10.3390/ijms24043062

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China trials

Trials by the same sponsor.

NCT06164288 — Safety and Efficacy Study of hAESCs Therapy for aGVHD · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04209712 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04209712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing